Evidence map›Paper›PMID 39880824›Full record

ArticleNature communications2025

Gemistocytic tumor cells programmed for glial scarring characterize T cell confinement in IDH-mutant astrocytoma.

Levi van Hijfte, Marjolein Geurts, Iris de Heer, Santoesha A Ghisai, Hayri E Balcioglu, Youri Hoogstrate, Wies R Vallentgoed, Rania Head, Rosa Luning, Thierry van den Bosch and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Glial Cells in Behavioral and Psychological Symptoms of Alzheimer's Disease.International journal of molecular sciences · 2026
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Levi van HijfteDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. l.vanhijfte@erasmusmc.nl.ORCID http://orcid.org/0000-0002-1402-6784
Marjolein GeurtsDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Iris de HeerDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Santoesha A GhisaiDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-3289-4294
Hayri E BalciogluDepartment of Medical Oncology, Laboratory of Tumor Immunology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-0225-0180
Youri HoogstrateDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0003-2166-0676
Wies R VallentgoedDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0001-6373-7710
Rania HeadDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Rosa LuningDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Thierry van den BoschDepartment of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands.
Bart WestermanDepartment of Neurosurgery, Amsterdam UMC/VUMC, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-9898-9616
Pieter WesselingDepartment of Pathology, Amsterdam UMC/VUMC and Brain Tumour Center, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-5453-5201
Johanna A JoyceDepartment of Oncology, University of Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-6332-2598
Pim FrenchDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. p.french@erasmusmc.nl.ORCID http://orcid.org/0000-0002-0668-9529
Reno DebetsDepartment of Medical Oncology, Laboratory of Tumor Immunology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. j.debets@erasmusmc.nl.ORCID http://orcid.org/0000-0002-3649-807X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isocitrate dehydrogenase 1/2 mutant (IDHmt) astrocytoma is considered a T cell-deprived tumor, yet little is known regarding the phenotypes underlying T cell exclusion. Using bulk, single nucleus and spatial RNA and protein profiling, we demonstrate that a distinct spatial organization underlies T cell confinement to the perivascular space (T cell cuff) in IDHmt astrocytoma. T cell cuffs are uniquely characterized by a high abundance of gemistocytic tumor cells (GTC) in the surrounding stroma. Integrative analysis shows that GTC-high tumors are enriched for lymphocytes and tumor associated macrophages (TAM) and express immune cell migration and activation programs. Specifically, GTCs constitute a distinct sub-cluster of the astrocyte-like tumor cell state that co-localizes with immune reactive TAMs. Neighboring GTCs and TAMs express receptor-ligand pairs characteristic of reactive astrogliosis and glial scarring, such as SPP1/CD44 and IL-1β/IL1R1. Collectively, we reveal that T cell confinement in IDHmt astrocytomas associates with GTC-TAM networks that mimic glial scarring mechanisms.

Indexed as

AstrocytomaBrain NeoplasmsIsocitrate DehydrogenaseT-LymphocytesAstrocytesCell MovementFemaleGliosisHumansMaleMutationTumor-Associated MacrophagesIDH1 protein, humanIDH2 protein, humanIsocitrate Dehydrogenase

Identifiers

PMID39880824
PMCPMC11779865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.